MIRM
NASDAQMirum Pharmaceuticals Inc.
Price$98.02-1.16 (-1.17%)
01:45 PM07:45 PM
News · 26 weeks85+100%
2026-03-012026-08-23
Mix4490d
- Insider23(52%)
- SEC Filings10(23%)
- Other8(18%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- INSIDERSVP, GLOBAL CONTROLLER Howe Jolanda exercised 40,000 shares at a strike of $6.27 and sold $4,000,000 worth of shares (40,000 units at $100.00) (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Bjerkholt Eric sold $599,510 worth of shares (6,001 units at $99.90) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 36,355 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Peetz Christopher sold $1,978,402 worth of shares (20,000 units at $98.92) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $2.94 (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 26,050 shares of common stock and 34,590 restricted stock units ("RSUs") to 19 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $98.70 per share, which is equal to the closing price of Mirum’s common stock on Augu
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form SCHEDULE 13G filed by Mirum Pharmaceuticals Inc.SCHEDULE 13G - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- INSIDERSVP, GLOBAL CONTROLLER Howe Jolanda sold $193,734 worth of shares (1,840 units at $105.29) as part of a pre-agreed trading plan, decreasing direct ownership by 59% to 1,274 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 10-Q filed by Mirum Pharmaceuticals Inc.10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- SECMirum Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- PRMirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update- Q2 2026 net product sales of $176 million - 2026 net product sales guidance increased to $680 million to $700 million - Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus due to PSC - Pre-NDA meeting held for volixibat in cholestatic pruritus due to PSC; additional discussions planned before potential NDA submission, now targeted in H1 2027 - Enrollment completed in VANTAGE study of volixibat in cholestatic pruritus due to PBC; data expected Q1 2027 - Conference call to provide business updates today, August 5 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financ
- PRMirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will report second quarter 2026 financial results on August 5, 2026. Mirum will also host a conference call to discuss the second quarter 2026 financial results and recent corporate progress. Conference call details: Wednesday, August 5, 2026 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: + 1 833 461 5787 International: +1 585 542 9983 Access Code: 789239699 You may also access the call via webcast by visiting the Investors section of Mirum’s corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) is a
- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on July 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 6,300 shares of common stock and 9,300 restricted stock units ("RSUs") to 6 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $122.13 per share, which is equal to the closing price of Mirum’s common stock on July 10,
- INSIDERCHIEF EXECUTIVE OFFICER Peetz Christopher exercised 20,000 shares at a strike of $2.94 and sold $2,445,382 worth of shares (20,000 units at $122.27) as part of a pre-agreed trading plan (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Bjerkholt Eric sold $611,273 worth of shares (5,000 units at $122.25) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 42,181 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- INSIDERSVP, GLOBAL CONTROLLER Howe Jolanda sold $326,520 worth of shares (2,721 units at $120.00) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 3,114 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSVP, GLOBAL CONTROLLER Howe Jolanda sold $264,458 worth of shares (2,594 units at $101.95) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 5,835 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 8-K filed by Mirum Pharmaceuticals Inc.8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- INSIDERSEC Form 4 filed by Director Walbert Timothy P4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Cardon Lon4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Ramasastry Saira4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairey William4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
MIRM FAQ
7 questionsWhat does Mirum Pharmaceuticals Inc. do?
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was...Where does MIRM stock trade?
Mirum Pharmaceuticals Inc. (MIRM) is listed on NASDAQ.What sector and industry is MIRM in?
Mirum Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mirum Pharmaceuticals Inc. go public?
Mirum Pharmaceuticals Inc. (MIRM) completed its IPO in 2019.What are analysts saying about MIRM?
Mirum Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-06-02. Recent price targets cluster around $4800.00.What companies are similar to MIRM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MIRM side-by-side with any of them on Quantisnow.How can I track MIRM on Quantisnow?
Quantisnow aggregates Mirum Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIRM to receive live email and push alerts on every new disclosure.